Connect with us

Press Release

Texas Billionaire Investing in Colombian Natural Gas Ahead of Projected Shortage

Published

on

–News Direct–

Source: Freepik
Source: Freepik

Despite its significant potential, Colombias energy sector is heading towards a major natural gas shortage by next year.

The oil and gas market is the key to Colombias national revenue, accounting for roughly 10% of GDP and 20% of exports. However, decreasing onshore production, delayed start-up of new offshore discoveries and President Gustavo Petro's focus on renewable energy are creating ongoing challenges in the sector.

This shortage is compounded by the challenges caused by El Nio and declining oil and natural gas reserves, as Colombia strives to maintain its position in the global energy market. El Nio has reduced hydropower generation in Colombia, increasing reliance on natural gas for electricity and boosting demand amid a tight supply.

By 2025, Colombia's natural gas supply will fall short of demand by 17% according to state-owned oil producer Ecopetrol SA. Whats more, Colombia's proven oil and natural gas reserves can last only around seven more years at the current extraction rate.

While recent gas discoveries offer some hope, Colombia is still grappling with the challenge of declining reserves and struggling production. In response, Colombia's state-run oil company, Ecopetrol, plans to invest up to $6.7 billion in 2024 to boost exploration and production activities, as well as developing new technologies to improve efficiency and sustainability in the sector.

Rod Lewis, founder of Lewis Energy Group and self-made billionaire, sees major potential in Colombias natural gas market and in Latin America, in general.

In the early 2000s, Lewis established a private subsidiary named Lewis Energy Colombia, which has operated in Colombia for 17+ years, with a significant runway ahead to grow and help meet the growing natural gas demand.

But to realize its full potential, it needed a dedicated and experienced management team, which is where the newly listed TSXVs LNG Energy Group Corp. (TSXV:LNGE) (OTCQB:LNGNF) (FRA:E26) comes in.

LNG Energy Group acquired Lewis Energy Colombia, Inc. in August of 2023 and went public on the TSXV the following month on September 12, 2023. Its management and board of directors bring together a combination of financial, legal and operational experience to grow the business rapidly and capitalize on the Latin American energy opportunities identified by Rod Lewis. He remains the largest investor in LNG Energy Group, which speaks volumes about his commitment to Colombia, Latin America and the team selected to drive business value.

LNG Energy Group Targets Ambitious Growth in 2024, Outlines Robust Production and Financial Goals

After a year focused on strategic acquisitions and financial structuring, particularly with the successful acquisition of Lewis Energy Colombia, LNG Energy Group Corp. (TSXV:LNGE) (OTCQB:LNGNF) (FRA:E26) is now turning its focus towards enhancing its portfolio of producing wells.

LNG Energy recently announced its 2024 production and capital guidance, signaling a promising year ahead with significant operational and financial milestones.

The company expects to achieve a gross production rate of between 40 million cubic feet equivalent per day (MMcfe/d) and 44 MMcfe/d in 2024, which is anticipated to generate an EBITDA of between US$33 million and US$39 million, assuming an average gas price of US$7.50 per thousand cubic feet (Mcf).

LNG Energy Group has identified more than 20 prospects that hold over 1 trillion cubic feet of prospective resources1 and with an exploration and development budget of $10-$12 million, the company is planning a five to six well work-over campaign and drilling one development well and two to four exploration wells in 2024.

These efforts are expected to significantly boost production by up to 15% year-over-year to 22 MMcfe/d net.

LNG Energy Group also plans to capitalize on take-or-pay contracts already in place, which have a locked-in weighted average natural gas sales price of $7.50 per thousand cubic feet ($/Mcf) for a volume of 18.1 million cubic feet per day (MMcf/d). Operating netback is anticipated to be between $5.40 and $5.50/Mcfe.

These contracts are particularly significant, considering Colombias soaring gas prices which are three times higher than the Henry Hub benchmark and AECO prices. LNG Energy Group's ability to secure prices averaging US$8.40/Mcf, and expecting US$7.50/Mcf for 2024 represents a substantial premium to US natural gas prices and underscore the competitive edge these contracts offer.

LNG Energy Group Corp. (TSXV:LNGE) (OTCQB:LNGNF) (FRA:E26) also recently announced its 2023 year-end reserves evaluation results, which revealed a notable 26% increase in the before-tax NPV10 value of its Proved plus Probable reserves to US$306 million, or C$2.67 per share.

The value of its Proved (1P) reserves reached US$171 million (C$1.49 per share), while its Proved plus Probable plus Possible (3P) reserves increased to US$577 million (C$5.04 per share).

By the end of 2023, the companys 1P reserves had a reserve life index of 7.9 years, and its 2P reserves had a reserve life index of 14.3 years. Additionally, over the last three years, LNG Energy has maintained a net reserves replacement ratio of 193% on a 1P basis and 336% on a 2P basis, indicating strong reserve growth and sustainability prospects. The company estimates it can produce at its current rate for nearly 8 years with its proven reserves and over 14 years with its proven and probable reserves.

The current market price of the Companys common shares represents a significant discount to the NPV10 for 1P reserves which is C$1.49 per share, said Pablo Navarro, LNG Energys Chairman and CEO. The Company has a reserves life index of 7.9 years on a 1P basis and a net reserves replacement ratio of 193% on a 1P basis. These reserves are located on acreage that represent less than 2% of our total acreage and we look forward to launching our 2024 activity set.

With over 40 years of experience in natural gas and more than 17 years of operations in Colombia, LNG Energy Group understands how to grow in international jurisdictions and is well-positioned to lead the countrys transition.

Click here to learn more about LNG Energy Group Corp. (TSXV:LNGE) (OTCQB:LNGNF) (FRA:E26).

[1] https://cdn-ceo-ca.s3.amazonaws.com/1iitanp-Canaccord%20Initiating%20Report.pdf

Disclaimer

1) The author of the Article, or members of the authors immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on research and understanding of the sector.

2) The Article was issued on behalf of and sponsored by, LNG Energy Group Corp. Market Jar Media Inc. has or expects to receive from LNG Energy Group Corp.s Digital Marketing Agency of Record (Native Ads Inc) one thousand five hundred USD for this article.

3) Statements and opinions expressed are the opinions of the author and not Market Jar Media Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Market Jar Media Inc. for this Article. Market Jar Media Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Market Jar Media Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Market Jar Media Inc. relies upon the authors to accurately provide this information and Market Jar Media Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. All investments carry risk and each reader is encouraged to consult with his or her individual financial professional. Any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Market Jar Media Inc.'s terms of use and full legal disclaimer as set forth here. This Article is not a solicitation for investment. Market Jar Media Inc. does not render general or specific investment advice and the information on pressreach.com should not be considered a recommendation to buy or sell any security. Market Jar Media Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on pressreach.com.

5) Market Jar Media Inc. and its respective directors, officers and employees hold no shares for any company mentioned in the Article.

6) This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, forward-looking statements), which reflect management's expectations regarding LNG Energy Group Corp.s future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as predicts, projects, targets, plans, expects, does not expect, budget, scheduled, estimates, forecasts, anticipate or does not anticipate, believe, intend and similar expressions or statements that certain actions, events or results may, could, would, might or will be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to LNG Energy Group Corp.s industry; (b) market opportunity; (c) LNG Energy Group Corp.s business plans and strategies; (d) services that LNG Energy Group Corp. intends to offer; (e) LNG Energy Group Corp.s milestone projections and targets; (f) LNG Energy Group Corp.s expectations regarding receipt of approval for regulatory applications; (g) LNG Energy Group Corp.s intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) LNG Energy Group Corp.s expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of managements experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute LNG Energy Group Corp.s business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) LNG Energy Group Corp.s ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) LNG Energy Group Corp.s ability to enter into contractual arrangements with additional parties; (e) the accuracy of budgeted costs and expenditures; (f) LNG Energy Group Corp.s ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption to as a result of CV-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of LNG Energy Group Corp. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) LNG Energy Group Corp.s operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as CV-19 may adversely impact LNG Energy Group Corp.s business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing LNG Energy Group Corp.s business operations (e) LNG Energy Group Corp. may be unable to implement its growth strategy; and (f) increased competition.

Except as required by law, LNG Energy Group Corp. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither does LNG Energy Group Corp. nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this document. Neither LNG Energy Group Corp. nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this document by you or any of your representatives or for omissions from the information in this document.

7) Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of LNG Energy Group Corp. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of LNG Energy Group Corp. or such entities and are not necessarily indicative of future performance of LNG Energy Group Corp. or such entities.

8) Investing is risky. The information provided in this article should not be considered as a substitute for professional financial consultation. Users should be aware that investing in any form carries inherent risks, and as such, there is a possibility of losing some or all of their investment. The value of investments can fluctuate significantly within a short period, and investors must understand that past performance is not indicative of future results. Additionally, users should exercise caution as transactions involving investments may be irreversible, even in cases of fraud or accidental actions. It is crucial to acknowledge that rapidly evolving laws and technical issues can have adverse effects on the usability, transferability, exchangeability, and value of investments. Furthermore, users must be cognizant of potential security risks associated with their investment activities. Individuals are strongly encouraged to conduct thorough research, seek professional advice, and carefully evaluate their risk tolerance before engaging in any investment endeavors. Market Jar Media Inc. is neither an investment adviser nor a broker-dealer. The information presented on the website is provided for informative purposes only and is not to be treated as a recommendation to make any specific investment. No such information on PressReach.com constitutes advice or a recommendation.

Contact Details

James Young

+1 800-340-9767

campaigns@pressreach.com

Company Website

https://pressreach.com

View source version on newsdirect.com: https://newsdirect.com/news/texas-billionaire-investing-in-colombian-natural-gas-ahead-of-projected-shortage-437476572

MarketJar

comtex tracking

COMTEX_449911092/2655/2024-03-27T08:32:55

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

South Africa’s Trailers4Sale Offers Global Insight into Transport Efficiency

Published

on

Trailers4Sale, a South Africa-based company, is gaining international attention for its versatile trailer solutions. Originally established to provide durable trailers for Mzansi Power’s generator needs, the company has expanded its product range to serve various industries, including agriculture, recreation, and construction. With a focus on adaptability and quality, Trailers4Sale offers an extensive selection of trailers and essential parts, making it a valuable partner in the evolving global logistics landscape. While primarily serving Southern Africa, the company’s products are increasingly relevant to internationals market, presenting an opportunity for businesses seeking reliable transport solutions.

Vanderbijlpark, Gauteng, South Africa, 18th Oct 2024 – Trailers4Sale, a company rooted in the dynamic and diverse economy of South Africa, is redefining the trailer industry by leveraging its expertise in designing adaptable and versatile transport solutions. With a focus on innovation, the company has developed trailers suited to industries ranging from agriculture to recreation, while also offering a wide range of essential trailer parts. Now, with logistical demands increasing worldwide, Trailers4Sale’s products are poised to play a role in shaping global transport strategies—catching the attention of the local market.

Rethinking Transport with Versatile Trailers

Trailers4Sale’s journey began with a focus on building strong, durable trailers for South Africa’s generator market through its parent company, Mzansi Power. As demand for trailers grew beyond energy transport, the company expanded to produce a wide array of trailer types that meet various industry needs. Today, Trailers4Sale offers everything from multi-purpose trailers and flatbed trailers to highly specialized models like cattle trailers and Bomac trailers for heavy-duty applications.

Southern Africa’s landscape has long been a hub for trade, agriculture, and industrial growth, which has allowed Trailers4Sale to develop trailers designed for flexibility and reliability. These qualities align with the evolving needs of industries worldwide, where businesses increasingly rely on adaptable transport solutions to improve efficiency.

An Industry Adapting to Change

The trailer industry globally has seen a surge in demand as businesses in sectors like construction, agriculture, and logistics recognize the importance of optimizing transport. What makes Trailers4Sale stand out is its ability to address these challenges with customizable solutions. Trailers4Sale’s approach centers on providing trailers that can be adapted to various needs—whether it’s for transporting heavy equipment, recreational vehicles, or livestock.

Trailers4Sale is uniquely positioned to meet its demands by offering trailers that suit a variety of terrains and functions, products which are increasingly relevant to the American landscape. From motorbike trailers for recreational use to multi-purpose trailers for commercial applications, the company’s range is designed to align with the growing expectations for versatile, durable transport solutions.

Bridging the Gap with Practical Solutions

One of Trailers4Sale’s most significant contributions is in offering not just trailers, but a full suite of parts and accessories. Businesses looking for reliable access to parts like rims, lights, wiring, or jockey wheels will find that Trailers4Sale’s inventory is designed to provide easy maintenance and repair solutions, ensuring transport operations run smoothly.

This holistic approach has allowed the company to form strong partnerships with both local and international businesses, providing high-quality products that have earned the trust of its customers.

Built on Expertise and Service

A key driver behind Trailers4Sale’s success has been its ability to combine innovation with customer care. The company prides itself on offering personalized guidance to help businesses select trailers that meet their specific needs. With the increasing complexity of global logistics, having a partner who can offer expert advice, backed by years of experience in a region known for its economic growth, positions Trailers4Sale as a unique player in the industry.

“We believe that trailers are more than just transport tools; they are critical components in a business’s overall efficiency,” says Evert Janse van Rensburg, Founder of Trailers4Sale. “South Africa’s thriving industries have shaped our understanding of what businesses need to succeed, and we are eager to share this expertise globally.”

Looking to the Future: A Global Perspective

As global industries seek smarter transport solutions, Trailers4Sale is well-placed to support this shift by offering products that meet high standards of performance and reliability. For companies navigating new logistical challenges, Trailers4Sale’s comprehensive approach—offering both trailers and essential parts—presents a valuable opportunity to enhance their operations.

For more information about Trailers4Sale’s products and services, visit their website.

Media Contact

Organization: Trailers4Sale

Contact Person: Evert Janse van Rensburg

Website: https://trailers4sale.co.za

Email: Send Email

Contact Number: +27658316889

Address: 19A Michelin St

Address 2: Vanderbijlpark N. W. 7

City: Vanderbijlpark

State: Gauteng

Country: South Africa

Release Id: 18102418608

The post South Africa’s Trailers4Sale Offers Global Insight into Transport Efficiency appeared on King Newswire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

OXYENERGY AGELESS SWITCH is leading a revolutionary new era in anti-aging with groundbreaking innovation.

Published

on

New Zealand, 18th Oct 2024 – In the context of a rapidly aging global population and a growing awareness of health among consumers, the demand for premium oral anti-aging nutritional products is surging. OXYENERGY, a specialized nutritional brand from New Zealand, has developed and produced AGELESS SWITCH, a cutting-edge product based on the concept of “comprehensive anti-aging and stem cell activation,” aiming to create a truly functional anti-aging solution. This innovative approach has quickly garnered widespread attention worldwide, with numerous prominent media outlets covering the product, and endorsements from respected professionals, including professors, nutritionists, and international pageant winners. As a result, AGELESS SWITCH PQQ has gained significant traction, emerging as a dominant new trend in the oral beauty and anti-aging market.

PQQ (Pyrroloquinoline Quinone) holds a highly esteemed position in the fields of biomedical and nutritional sciences, earning the title of “King of Immunity.” Due to its complex extraction process, the purified form of PQQ commands an exceptionally high price on the international market—exceeding the value of gold by over a thousand times. For a long time, this made PQQ available only for research purposes. However, further studies revealed that PQQ can effectively target and neutralize free radicals in the body, mitigating oxidative stress damage to cellular structures. This potent protection of cellular health surpasses that of traditional antioxidants, leading to the widespread adoption of PQQ in anti-aging products.

The AGELESS SWITCH PQQ product builds on traditional PQQ formulations, seeking innovative breakthroughs in both technology and formulation. It focuses on stem cell activation technology and sets a new market benchmark with a high concentration of 50mg per capsule and over 99% purity achieved through patented extraction processes. This product is further enhanced by premium ingredients such as Ergothioneine, Pterostilbene, and Apple Stem Cell Extract. Utilizing advanced 6-in-1 Black Gold Anti-Aging Technology, it upgrades its antioxidant capacity by 60,000 times, establishing the Black Gold Anti-Aging Pyramid and offering a three-step targeted anti-aging solution for full-body rejuvenation.

OXYENERGY’s AGELESS SWITCH PQQ stands out in the industry with its pioneering biotechnology and advanced formulation, positioning itself as a trailblazer driving further development in the anti-aging sector. Its excellent product reputation has sparked a global following, earning it the nickname “the black bandage of oral supplements.” This has ignited an unprecedented AGELESS SWITCH PQQ trend in the global anti-aging market, with countless consumers adopting it in their daily routines to affirm their status as anti-aging enthusiasts. Industry experts have remarked, “The global era of OXYENERGY AGELESS SWITCH has arrived!”

As a global pioneer in the field of dietary nutrition, the New Zealand brand OXYENERGY consistently stays at the forefront of industry development with its forward-thinking vision and scientific expertise. Committed to advancing the anti-aging sector and other health-related fields, OXYENERGY continues to drive breakthroughs and innovations in the global health industry. The brand is leading more consumers toward a younger, healthier future.

 

Media Contact

Organization: OXYENERGY

Contact Person: sunny chen

Website: https://www.oxyenergy-labs.com/

Email: Send Email

Country: New Zealand

Release Id: 18102418595

The post OXYENERGY AGELESS SWITCH is leading a revolutionary new era in anti-aging with groundbreaking innovation. appeared on King Newswire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

China Medical System:First Ruxolitinib Cream’s Prescriptions for Vitiligo Issued in the Greater Bay Area

Published

on

SHENZHEN, CHINAChina Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. The Product’s new drug application (NDA) was approved by the Pharmaceutical Administration Bureau (ISAF) of Macau on 11 April 2024, and subsequently the Product was approved by the Guangdong Provincial Medical Products Administration on August 19 through the “Hong Kong and Macau Medicine and Equipment Connect” policy, which officially introduced ruxolitinib cream for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age, providing a novel treatment option for patients with relevant indication into designated medical institutions in the Mainland of Greater Bay Area.

 

In addition, on 24 September, the NDA for vitiligo indication of ruxolitinib cream has been accepted by the National Medical Products Administration of China (NMPA). In accordance with the relevant regulations of the drug real-world data application pilot program in the Hainan Boao Lecheng International Medical Tourism Pilot Zone (the “Pilot Zone”), CMS has conducted a real-world study on ruxolitinib cream in China. The results have shown positive efficacy, which is consistent with the key outcomes of global pivotal clinical studies. All secondary efficacy endpoints showed a trend of benefit consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with longer treatment duration. Meanwhile, through the safety monitoring data of the Pilot Zone, no new safety events have been identified. Adverse events mostly had severity levels of grade 1 or 2. No adverse event (AE) leading to discontinuation or withdrawal, and no serious adverse event (SAE) related to the study drug occurred.

 

If the Product is successfully approved for marketing in Mainland China, it will be the first prescription drug approved by NMPA for repigmentation in vitiligo, bringing this novel treatment hopes for Chinese vitiligo patients.

 

Furthermore, on 12 August 2023, the Product was approved by Hainan Medical Products Administration for Urgent Clinical Import, and officially became available to applicable patients in the Pilot Zone on August 18, for the topical treatment of non-segmental vitiligo in adults and adolescents aged 12 and above with facial involvement. Benefiting from the Early and Pilot Implementation Policy granted by the state to Hainan Free Trade Port and the Pilot Zone, patients with vitiligo in China can apply for the Product in Boao Super Hospital first and receive treatment from the expert team. As of 30 June 2024, more than 3,200 patients have been treated with ruxolitinib cream in Boao Super Hospital.

 

CMS has always been patient-oriented and innovation-driven based on clinical needs, continuously striving to improve drug accessibility. Benefited from the “Hong Kong and Macau Medicine and Equipment Connect” policy, ruxolitinib cream was approved for use in the Greater Bay Area and completed its first batch of prescriptions, shortening the time difference for Chinese vitiligo patients to use innovative drug and benefiting more domestic patients. Looking forward to the future, the Group will continuously strive to meet the unmet needs of Chinese patients, continuously explore novel drugs with international quality, and efficiently promote products’ clinical development and commercialization, so as to bring more quality pharmaceutical products through differentiated innovation-breakthrough, to safeguard the health and life-quality of patients.

 

About ruxolitinib cream

Ruxolitinib cream (Opzelura), a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is approved by the U.S. Food & Drug Administration for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older. As of now, it is the first and only treatment for repigmentation approved for use in the United States[1]. Ruxolitinib cream (Opzelura) is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable[2]. In Europe, ruxolitinib cream (Opzelura) is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].

 

On 2 December 2022, the Group through a subsidiary of the Company, a dermatology medical aesthetic company (CMS Skinhealth) entered into a Collaboration and License Agreement (the License Agreement) with Incyte for topical formulations of ruxolitinib for the treatment of autoimmune and inflammatory dermatology diseases. In accordance with the License Agreement, the Group through CMS Skinhealth received an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (Indonesia, Philippines, Vietnam, Thailand, Myanmar, Malaysia, Cambodia, Laos, Singapore, Timor-Leste and Brunei Darussalam) (the Territory) and a non-exclusive license to manufacture the Product in the Territory. The License Agreement commenced on its effective date and has a royalty term of ten years from the date of the commercial sale of the Product in the Territory (the Royalty Term). Upon the expiration of the Royalty Term, the License Agreement may be renewed for a period of ten years thereafter (the Initial Extended Royalty Term) as per certain conditions defined in the License Agreement. Upon the expiration of the Initial Extended Royalty Term, the License Agreement may be extended for a period otherwise agreed by both sides as per certain conditions defined in the License Agreement.

 

Incyte has worldwide rights for the development and commercialization of the Product, marketed in the United States and Europe as Opzelura®. Opzelura and the Opzelura logo are registered trademarks of Incyte.

 

About vitiligo

Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 14 million vitiligo patients in China[4]. Non-segmental vitiligo patients account for approximately 85% of them. Topical corticosteroids (TCS) and calcineurin inhibitors (CI) are used off-label for non-segmental vitiligo, however, these therapies have clinical deficiencies with long-term adverse reactions of long-term treatment or limited efficacy[56].

 

About CMS

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

 

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.

 

CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a “bridgehead” for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.

 

Reference

  1. Drug approval information can be found on the FDA official website, as follows: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-t…
  2. Drug approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-an…
  3. Drug approval information can be found on the EMA official website, as follows: https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura
  4. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi:10.1016/S0140-6736(14)60763-7
  5. Consensus on the diagnosis and treatment of vitiligo (2021 version)
  6. Kubelis-López DE, Zapata-Salazar NA, Said-Fernández SL, Sánchez-Domínguez CN, Salinas-Santander MA, Martínez-Rodríguez HG, Vázquez-Martínez OT, Wollina U, Lotti T, Ocampo-Candiani J. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021 Aug;22(2):797. doi: 10.3892/etm.2021.10229. Epub 2021 May 25. PMID: 34093753; PMCID: PMC8170669.

 

CMS Disclaimer and Forward-Looking Statements

This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.

 

This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

 

Media Contact

Brand: China Medical System Holdings Ltd.

Contact: CMS Investor Relations

Email: ir@cms.net.cn

Website: https://web.cms.net.cn/en/home/

Source: China Medical System Holdings Ltd.

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST